Comprehensive Recovery Protocol

Overview

A multi-system regenerative framework designed for complex orthopedic recovery, advanced tissue repair, and structural regeneration. This protocol integrates angiogenic peptides, chondroprotective compounds, immune modulators, mitochondrial support, and growth hormone secretagogues to optimize recovery following major surgical intervention or extensive structural injury. It is intended for cases requiring sustained, multi-phase remodeling under close clinical supervision.

Clinical Targets

Joint replacement recovery
ACL reconstruction
Spinal fusion recovery
Complex multi-tissue injury
Advanced degenerative joint repair

Expected Outcomes

Accelerated structural tissue repair
Improved vascularization and perfusion
Enhanced cartilage and connective tissue regeneration
Reduced post-surgical inflammation
Optimized sleep-driven recovery cycles

Core Multi-System Stack

BPC-157

Administration Route: SubQ (local + systemic)
Dose: 500 mcg local + 250 mcg systemic
Frequency: Twice daily
Duration: 12 weeks

TB-500 (Thymosin β4)

Administration Route: SubQ
Dose: 2.0 mg
Frequency: Twice weekly (Weeks 1–4), then weekly (Weeks 5–12)
Duration: 12 weeks

AOD-9604

Administration Route: SubQ
Dose: 300–600 mcg
Frequency: Daily
Duration: 12 weeks

GHK-Cu

Administration Route: SubQ + Topical
Dose: 2 mg SubQ plus topical application
Frequency: Daily
Duration: 12 weeks

KPV

Administration Route: SubQ
Dose: 500 mcg
Frequency: Daily
Duration: 6 weeks (front-loaded)

CJC-1295 / Ipamorelin

Administration Route: SubQ
Dose: 100 mcg / 100 mcg
Frequency: Once daily (evening)
Duration: 12–16 weeks

DSIP

Administration Route: SubQ
Dose: 100–200 mcg
Frequency: Once nightly (30 minutes before bed)
Duration: 4–8 weeks

Phase Structure

Phase 1: Intensive Stabilization (Weeks 1–4)

Dual BPC-157 approach (local + systemic)
TB-500 twice weekly loading
AOD-9604 daily
GHK-Cu daily (SubQ + topical)
KPV daily (front-loaded anti-inflammatory support)
CJC-1295 / Ipamorelin nightly
DSIP nightly for sleep optimization

Phase 2: Active Remodeling (Weeks 5–8)

Continue BPC-157 dual dosing
TB-500 transition to weekly
Maintain AOD-9604 and GHK-Cu
Continue GH secretagogues
Taper KPV after Week 6

Phase 3: Structural Consolidation (Weeks 9–12+)

Continue AOD-9604 through Week 12
Maintain CJC-1295 / Ipamorelin as needed
Reduce BPC-157 to once daily if stable
Discontinue TB-500 at Week 12
DSIP discontinued once sleep architecture stabilized

Rationale

This is the most comprehensive and aggressive regenerative protocol in the orthopedic series and should be reserved for complex cases under close supervision. The dual BPC-157 strategy provides both targeted perilesional repair and systemic anti-inflammatory support. TB-500 enhances cellular migration into damaged tissues, while AOD-9604 supports cartilage preservation and structural remodeling. GHK-Cu enhances collagen synthesis and extracellular matrix restoration. KPV reduces inflammatory signaling during the early phase. CJC-1295/Ipamorelin elevate systemic growth hormone and IGF-1 to sustain long-term tissue remodeling. DSIP optimizes deep sleep architecture, which is critical for growth hormone–mediated repair.

Monitoring

Range of motion and functional assessment
Pain scoring (VAS)
Inflammatory markers when indicated
IGF-1 monitoring if GH secretagogues are used
Sleep quality assessment during DSIP use

Contraindications

Active malignancy
Pregnancy or breastfeeding
Uncontrolled endocrine disorders
Active systemic infection
Known hypersensitivity to components

Mathematical Calculation Tool

The calculator below allows mathematical concentration and volume calculations using variable vial strengths and reconstitution volumes. This tool is provided strictly for arithmetic reference.

Peptide Reconstitution Calculator

For Educational & Professional Reference Only

⚠️ This is a mathematical reference tool only. No medical or dosing advice is provided.

Clinical Disclaimer

This protocol is intended for informational and educational purposes for licensed healthcare professionals. These compounds and strategies are not intended to diagnose, treat, cure, or prevent any disease. Implementation requires patient-specific evaluation and clinical judgment.